Starpax Biopharma Inc.
- Proceeding
- CCAACompanies' Creditors Arrangement Act (RSC 1985, c. C-36, as amended)
- Court
- Superior Court of Québec · Commercial Division
- File
- 500-11-066112-257
- Industry
- Health care · Pharmaceuticals & biotech
Starpax Biopharma Inc. has been under CCAA protection in the Superior Court of Québec, Commercial Division, at Montréal since September 12, 2025, with Raymond Chabot Inc. acting as court-appointed controller. An interim order was granted on September 9, 2025, and on September 22 the Court approved a Sale and Investment Solicitation Process under which no break fee, expense reimbursement or similar payment is permitted. Phase 1 ran to a bid deadline of November 27, 2025; further bid deadlines of January 22, 2026 and February 13, 2026 are on the record. The controller's work has been dominated by preservation of the estate: property insurance, a temporary occupation agreement for the Starpax plant, essential utilities, IT and physical security, and protection of the company's patents and bacterial strain. The case remains active, with reporting to March 4, 2026.
2026-03-09 Second Amended and Restated Transition Order (in French) — Transition order (NOI → CCAA)
Third report: preservation continued, with property insurance renewed, a temporary occupation agreement negotiated with the landlord of the Starpax plant, utilities and security maintained, and patent agent liaison on the bacterial strain.
2026-03-04 Motion - Extension of stay and Approval of a transaction (in French) — Application / notice of application
The court approved a sale and investment solicitation process.
Source: Second Notice of the postponed dates SISP (in French)
Second report: controller managed preservation measures, reactivating property insurance, negotiating a temporary occupation agreement, maintaining essential utilities, installing IT and physical security, taking inventory, meeting former employees, and protecting intellectual property and the bacterial strain.
Under the approved process, Phase 1 ran to a bid deadline of November 27, 2025.
Source: 500-11-066112-257 - SISP Launch Notice with Appendix A - October 9, 2025
Further reference to the same September 22 order in the controller's French-language reporting; no separate relief recorded.
Source: Notice of the postponed deadline to select an offer (in French)
The same order approved the Sale and Investment Solicitation Process itself and barred any break fee, expense reimbursement or similar payment.
Source: Starpax - SISP Package
Controller's first report: statutory notifications made, conservatory measures put in place, receipts and disbursements brought under control through bank account closure, trust account opening and interim financing, and a sale and investment solicitation process developed for the debtor's business and assets.
2025-09-17 Amended Motion for Amended and Restated Transition Order (in French) — Application / notice of application
Interim order granted, three days before the CCAA proceeding formally commenced on September 12, 2025.
Source: 2025-09-09 Order to appoint a Managing Judge (in French)
2025-09-02 Motion for a Transition Order and Initial Order (in French) — Application / notice of application
Debtor
Starpax Biopharma Inc.
Monitor
Raymond Chabot
Bench
| Judge | Court | On this docket | Cases on record |
|---|---|---|---|
| Justice Ouellet | Superior Court of Québec | 5 orders, Sep 2025 – Jun 2026 | 10 cases on record |
| Justice Janetmichelin | Superior Court of Québec | 5 orders, Sep 2025 – Mar 2026 | 12 cases on record |
Counsel of record
| Party | Counsel | First seen | Source |
|---|---|---|---|
| CreditorFiducie Familiale Louis Audet | Fasken Martineau DuMoulin LLP | 4 Mar 2026 | Service list · 4 Mar 2026 |
| Creditorlocateur Me Maxime Champagne | Gowling WLG (Canada) LLP | 4 Mar 2026 | Service list · 4 Mar 2026 |
| CreditorMe Stéphane Hébert | Sylvestre Avocats Et Notaires | 4 Mar 2026 | Service list · 4 Mar 2026 |
| # | Priority class | Creditor | Amount | Source |
|---|---|---|---|---|
| 4 | Secured | Investissement Québec · in 105 casesTrustee's Creditor List, 'Amount Declared'; Amount Filed $0.00, Amount Admitted $0.00; Claim Status = Not Proven (N) — debtor: Starpax Biopharma Inc. · as of 19 Sep 2025 | $10.6M | 2025-09-19 Creditors' List |
| 4 | Secured | |||
| 4 | Secured | |||
| 8 | Unsecured | |||
| 8 | Unsecured | |||
| 8 | Unsecured | |||
| 8 | Unsecured | |||
| 8 | Unsecured | |||
| 8 | Unsecured | |||
| 8 | Unsecured |
112 more claims in 2 classes The stack holds Secured and Unsecured claims.
Every creditor and every amount, drawn to scale.
Card required. Nothing charged for 5 days. Cancel anytime.
Already a subscriber? Sign in.
See all plansClosed · the record states no distribution outcome.
As at ·
Cumulative receipts
$1.71M
As at 4 Mar 20262026-03-04 Third Report of the Monitor (in French)
Cash on hand
As at
Professional fees
As at
2 more reported figures, and the 2 totals the debtor stated at filing
Each one as the filing states it, with its source.
Card required. Nothing charged for 5 days. Cancel anytime.
Already a subscriber? Sign in.
See all plans| Date | Document | File |
|---|---|---|
2026-06-03 Order Ending of proceedings and Discharge of the Monitor (in French)
| PDF · Subscribers | |
2026-03-09 Approval and Vesting Order
| PDF · Subscribers | |
2026-03-09 Radiation and Reduction Order (in French)
| PDF · Subscribers | |
2026-03-09 Second Amended and Restated Transition Order (in French)
| PDF · Subscribers | |
| 2026-03-04 Motion - Extension of stay and Approval of a transaction (in French) | PDF · Subscribers | |
2026-03-04 Service List
| PDF · Subscribers | |
2026-03-04 Third Report of the Monitor (in French)
| PDF · Subscribers | |
Second Notice of the postponed dates SISP (in French)
| PDF · Subscribers | |
2026-02-27 Order - Extension of stay (in French)
| PDF · Subscribers | |
Notice of the postponed deadline to select an offer (in French)
| PDF · Subscribers | |
2026-01-12 Order - Prolongation of stay (in French)
| PDF · Subscribers | |
| 2026-01-06 Motion - Extension of stay (in French) | PDF · Subscribers | |
2026-01-06 Second report of the Monitor
| PDF · Subscribers | |
500-11-066112-257 - Amended Procedures for the Sale and Investment Solicitation Process - October 9, 2025
| PDF · Subscribers | |
500-11-066112-257 - SISP Launch Notice with Appendix A - October 9, 2025
| PDF · Subscribers | |
2025-09-22 Amended and Restated Transition Order (in French)
| PDF · Subscribers | |
2025-09-22 SISP Order (in French)
| PDF · Subscribers | |
2025-09-19 Creditors' List
| PDF · Subscribers | |
2025-09-19 First report of the Monitor (in French)
| PDF · Subscribers | |
| 2025-09-17 Amended Motion for Amended and Restated Transition Order (in French) | PDF · Subscribers | |
| Starpax - Avis aux créanciers - Notice to creditors | PDF · Subscribers | |
2025-09-12 Transition Order and Initial Order (in french)
| PDF · Subscribers | |
Starpax - SISP Package
| PDF · Subscribers | |
2025-09-09 Order to appoint a Managing Judge (in French)
| PDF · Subscribers | |
2025-09-02 Minutes of the hearing (in French)
| PDF · Subscribers | |
2025-09-02 Motion for a Transition Order and Initial Order (in French)
| PDF · Subscribers | |
2025-09-02 Report of the Proposed Monitor (in French)
| PDF · Subscribers | |
Filing titles and dates are public, and so is each filing's own page. The figures read from them are for subscribers.
CiteProceedings., “Starpax Biopharma Inc.” (CCAA), Superior Court of Québec · Commercial Division. Retrieved 4 November 2026, https://proceedings.ca/case/starpax-biopharma-inc